SanBio Company Limited
Research SanBio Company Limited (4592.T) on Bullrun: market cap JPY 78.14B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4592.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 78.14B
- Financial periodFY2026
- RevenueJPY 0
- Net income-JPY 3.84B
- Free cash flow-JPY 3.79B
Valuation Snapshot
latest market cap is JPY 78.14B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 0 | -JPY 3.84B | -JPY 3.79B | n/a | -52.55 | JPY 15.08B | JPY 1.24B | JPY 13.60B |
| FY2025 | JPY 0 | -JPY 2.88B | -JPY 3.61B | n/a | -40.48 | JPY 2.92B | JPY 397.00M | JPY 1.76B |
| FY2024 | JPY 0 | -JPY 2.64B | -JPY 4.82B | n/a | -40.48 | JPY 4.45B | JPY 665.00M | JPY 2.79B |
| FY2023 | JPY 0 | -JPY 5.56B | -JPY 7.44B | n/a | -95.99 | JPY 6.73B | JPY 933.00M | JPY 4.43B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 78.14B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About SanBio Company Limited
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company's research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage;
ETFs that hold SanBio Company Limited
US-listed ETFs
SanBio Company Limited is held by 11 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Core MSCI EAFE ETF (IEFA) | <0.01% | 0.07% |
| iShares Core MSCI International Developed Markets ETF (IDEV) | <0.01% | 0.04% |
| State Street SPDR Portfolio Developed World ex-US ETF (SPDW) | <0.01% | 0.03% |
| iShares MSCI EAFE Small-Cap ETF (SCZ) | 0.01% | 0.40% |
| iShares Core MSCI Pacific ETF (IPAC) | <0.01% | 0.09% |
| State Street SPDR Portfolio MSCI Global Stock Market ETF (SPGM) | <0.01% | 0.09% |
| iShares MSCI Japan Small-Cap ETF (SCJ) | 0.03% | 0.50% |
| iShares International Small-Cap Equity Factor ETF (ISCF) | 0.01% | 0.24% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SanBio Company Limited's market cap?
SanBio Company Limited's market capitalization is JPY 78.14B.
What does SanBio Company Limited do?
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury.